Abiopharma

BioCryst Pharmaceuticals Inc (BCRX) Reports Q3 2022 Financial Results BioCryst Pharmaceuticals Inc (BCRX) announced its financial results for the period ending Q3 2022. Key Financial Highlights:

• Revenue: 246
• Net Income: Not disclosed
• EPS: Not disclosed
• Cash and equivalents: 417483
  • planned for products and product candidates, may not provide regulatory clearances which may result in delay of planned clinical trials, may impose certain restrictions, warnings, or other requirements on products and product candidates, may impose a clinical hold with respect to product candidates, or may withhold, delay or withdraw market approval for products and product candidates; product candidates, if approved, may not achieve market acceptance; BioCryst’s ability to successfully commercialize its products and product candidates, manage its growth and compete effectively; risks related to the international expansion of BioCryst’s business; and actual financial results may not be consistent with expectations, including that revenue, operating expenses and cash usage may not be within management's expected ranges. Please refer to the documents BioCryst files periodically with the Securities and Exchange Commission, specifically BioCryst’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, all of which identify important factors that could cause the actual results to differ materially from those contained in BioCryst’s projections and forward-looking statements. BCRXW Investors:John Bluth+1 919 859 7910